SG147456A1 - Use of organic compounds - Google Patents

Use of organic compounds

Info

Publication number
SG147456A1
SG147456A1 SG200807826-3A SG2008078263A SG147456A1 SG 147456 A1 SG147456 A1 SG 147456A1 SG 2008078263 A SG2008078263 A SG 2008078263A SG 147456 A1 SG147456 A1 SG 147456A1
Authority
SG
Singapore
Prior art keywords
organic compounds
benazapril
ccb
mortality
administering
Prior art date
Application number
SG200807826-3A
Other languages
English (en)
Inventor
Ken Jamerson
Nab Malcolm Mac
Bertram Pitt
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG147456A1 publication Critical patent/SG147456A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
SG200807826-3A 2003-10-20 2004-10-19 Use of organic compounds SG147456A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51263403P 2003-10-20 2003-10-20

Publications (1)

Publication Number Publication Date
SG147456A1 true SG147456A1 (en) 2008-11-28

Family

ID=34465367

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200807826-3A SG147456A1 (en) 2003-10-20 2004-10-19 Use of organic compounds

Country Status (19)

Country Link
US (2) US20060233876A1 (fr)
EP (1) EP1776115A2 (fr)
JP (1) JP2007511473A (fr)
KR (1) KR20060120126A (fr)
CN (1) CN101137367A (fr)
AU (1) AU2004281541B2 (fr)
BR (1) BRPI0415530A (fr)
CA (1) CA2542757A1 (fr)
IL (1) IL174927A0 (fr)
IS (1) IS8470A (fr)
MA (1) MA28108A1 (fr)
MX (1) MXPA06004369A (fr)
NO (1) NO20062236L (fr)
RU (1) RU2006117198A (fr)
SG (1) SG147456A1 (fr)
TN (1) TNSN06111A1 (fr)
TW (1) TW200524591A (fr)
WO (1) WO2005037278A2 (fr)
ZA (1) ZA200602994B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10127130B2 (en) * 2005-03-18 2018-11-13 Salesforce.Com Identifying contributors that explain differences between a data set and a subset of the data set
US9940405B2 (en) 2011-04-05 2018-04-10 Beyondcore Holdings, Llc Automatically optimizing business process platforms
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
CN102008708B (zh) * 2009-07-14 2013-02-20 邬林祥 一种治疗高血压含雷米普利的复方制剂
EP2585051B2 (fr) 2010-06-23 2020-04-08 KRKA, tovarna zdravil, d.d., Novo mesto Formes pharmaceutiques à usage oral comprenant de la lercanidipine et de l'énalapril et leurs sels pharmaceutiquement acceptables
US10796232B2 (en) 2011-12-04 2020-10-06 Salesforce.Com, Inc. Explaining differences between predicted outcomes and actual outcomes of a process
US10802687B2 (en) 2011-12-04 2020-10-13 Salesforce.Com, Inc. Displaying differences between different data sets of a process
CN102440993B (zh) * 2011-12-08 2013-04-17 扬子江药业集团广州海瑞药业有限公司 一种氨氯地平和贝那普利的药物组合物
HUE028579T2 (en) * 2011-12-21 2016-12-28 Novartis Tiergesundheit Ag New combination
CN102688245A (zh) * 2012-06-11 2012-09-26 北京阜康仁生物制药科技有限公司 一种稳定的氨氯地平与贝那普利药用组合物及其制备方法
JP2014219945A (ja) * 2013-05-10 2014-11-20 富士通株式会社 治験情報出力装置、治験情報出力方法および治験情報出力プログラム
US20200111575A1 (en) * 2018-10-04 2020-04-09 Babylon Partners Limited Producing a multidimensional space data structure to perform survival analysis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162802A (en) * 1992-03-10 2000-12-19 Papa; Joseph Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor
EP0795327A1 (fr) * 1996-03-13 1997-09-17 Pfizer Inc. Utilisation de l'amlodipine pour le traitement et la prophylaxie de l'insuffisance cardiaque congestive d'origine non-ischémique
EP1365761A1 (fr) * 2000-12-18 2003-12-03 Novartis AG Combinaison therapeutique d'amlodipine et de benazepril
TW200306799A (en) * 2002-05-17 2003-12-01 Novartis Ag Combination of organic compounds

Also Published As

Publication number Publication date
WO2005037278A3 (fr) 2007-05-10
NO20062236L (no) 2006-07-19
KR20060120126A (ko) 2006-11-24
BRPI0415530A (pt) 2006-12-26
JP2007511473A (ja) 2007-05-10
AU2004281541B2 (en) 2008-05-01
US20060233876A1 (en) 2006-10-19
MXPA06004369A (es) 2006-06-14
TNSN06111A1 (en) 2007-11-15
AU2004281541A1 (en) 2005-04-28
ZA200602994B (en) 2008-03-26
US20080242659A1 (en) 2008-10-02
CA2542757A1 (fr) 2005-04-28
MA28108A1 (fr) 2006-08-01
EP1776115A2 (fr) 2007-04-25
IL174927A0 (en) 2008-04-13
CN101137367A (zh) 2008-03-05
TW200524591A (en) 2005-08-01
WO2005037278A2 (fr) 2005-04-28
IS8470A (is) 2006-05-16
RU2006117198A (ru) 2007-12-10

Similar Documents

Publication Publication Date Title
TNSN06111A1 (en) Tbenazpril and amlodipine for reducing cardiovascular morbidity
HUS1300066I1 (hu) 4-Oxokinolin vegyületek és ezek alkalmazása HIV integráz inhibitorként
AU2003274601A1 (en) Dipeptidyl peptidase iv inhibiting fluorinated cyclic amides
AU2003278088A1 (en) Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors
HK1071360A1 (en) 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
AU2003248872A1 (en) Hiv integrase inhibitors
IL165101A0 (en) Combination of a dpp IV inhibitor and a cardiovas cular compounds
DK1507529T3 (da) Kombination indeholdende valsartan, amlodipin og hydrochlorthiazid
NO20041709L (no) N-substituerte pyrrolidinderivater som dipeptidyl peptidase IV inhibitorer
AU2003232405A1 (en) Flourinated cyclic amides as dipeptidyl peptidase iv inhibitors
AP2004003191A0 (en) Pseudopolymorphic forms of HIV protease inhibitor.
ZA200408423B (en) Novel tetrahydropyridine derivatives as renin inhibitors.
AU2002952946A0 (en) Dpp-iv inhibitor
AU2003228796A1 (en) Cholinesterase inhibitors to prevent injuries caused by chemicals
AU2003230392A8 (en) Beta-secretase inhibitors
NO20044269L (no) Smamolekylaere inntrengningsinhibitorer
IL164898A0 (en) Heterotricyclyl 6-alkylidene-penems as beta-lactamase inhibitors
AU2003217444A1 (en) A compound as cholinesterase inhibitor and its isolation from fungus sporotrichum species
AU2002361117A1 (en) 5-membered cyclic compounds
AU2003274059A8 (en) Combination of a trioxopyrimidine compound inhibitor and an anti-tumor agent, and uses thereof
AU2003282866A1 (en) Methods of preventing morbidity and mortality by perioperative administration of a blood clotting inhibitor
AU2003232362A8 (en) 4-pyrazol-phenylalanine derivatives as ace-nep inhibitors
AU2003287325A8 (en) N-cycloalkylglycines as hiv protease inhibitors
GB2391424B (en) A detecting circuit for detecting the presence of a headset connected to a telephone,and a method for detecting a headset connected to a telephone
DE50310603D1 (de) Splittergeschoss